Spatial analysis of microRNA regulation at defined tumor hypoxia levels reveals biological traits of aggressive prostate cancer
- PMID: 39329425
- DOI: 10.1002/path.6344
Spatial analysis of microRNA regulation at defined tumor hypoxia levels reveals biological traits of aggressive prostate cancer
Abstract
Mechanisms regulating the gene expression program at different hypoxia severity levels in patient tumors are not understood. We aimed to determine microRNA (miRNA) regulation of this program at defined hypoxia levels from moderate to severe in prostate cancer. Biopsies from 95 patients were used, where 83 patients received the hypoxia marker pimonidazole before prostatectomy. Forty hypoxia levels were extracted from pimonidazole-stained histological sections and correlated with miRNA and gene expression profiles determined by RNA sequencing and Illumina bead arrays. This identified miRNAs associated with moderate (n = 7) and severe (n = 28) hypoxia and predicted their target genes. The scores of miRNAs or target genes showed prognostic significance, as validated in an external cohort of 417 patients. The target genes showed enrichment of gene sets for cell proliferation and MYC activation at all hypoxia levels and PTEN inactivation at severe hypoxia. This was confirmed by RT-qPCR for MYC and PTEN, by Ki67 immunohistochemistry, and by gene set analysis in an external cohort. To assess whether miRNA regulation occurred within the predicted hypoxic regions, a method to quantify co-localization of multiple histopathology parameters at defined hypoxia levels was applied. A high Ki67 proliferation index co-localized significantly with hypoxia at all levels. The co-localization index was strongly associated with poor prognosis. Absence of PTEN staining co-localized significantly with severe hypoxia. The scores for miRNAs correlated with the co-localization index for Ki67 staining and hypoxia, consistent with miRNA regulation within the overlapping regions. This was confirmed by showing miR-210-3p expression within severe hypoxia by in situ hybridization. Cell line experiments (22Rv1, PC3) were conducted to determine whether miRNAs and target genes were regulated directly by hypoxia. Most of them were hypoxia-unresponsive, and probably regulated by other mechanisms such as MYC activation. In conclusion, in aggressive, hypoxic prostate tumors, cancer cells exhibit different proliferative gene expression programs that is regulated by miRNAs and depend on whether the cells reside in moderate or severe hypoxic regions. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Keywords: MYC; PTEN; gene expression; hypoxia; miRNA; pimonidazole; prostate cancer; spatial biology.
© 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Similar articles
-
MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.Cell Death Dis. 2018 Feb 7;9(2):167. doi: 10.1038/s41419-017-0241-y. Cell Death Dis. 2018. PMID: 29415999 Free PMC article.
-
Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.PLoS One. 2017 Jun 26;12(6):e0179543. doi: 10.1371/journal.pone.0179543. eCollection 2017. PLoS One. 2017. PMID: 28651018 Free PMC article.
-
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.Cancer. 2012 Dec 15;118(24):6063-71. doi: 10.1002/cncr.27689. Epub 2012 Jun 6. Cancer. 2012. PMID: 22674438 Free PMC article.
-
miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis.J Pathol. 2020 Nov;252(3):239-251. doi: 10.1002/path.5514. Epub 2020 Sep 15. J Pathol. 2020. PMID: 32710569
-
Recent scenario of microRNA as diagnostic and prognostic biomarkers of prostate cancer.Urol Oncol. 2017 Mar;35(3):92-101. doi: 10.1016/j.urolonc.2016.10.019. Epub 2016 Nov 24. Urol Oncol. 2017. PMID: 27890424 Review.
References
-
- Milosevic M, Warde P, MénardMenard C, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clinical Cancer Res 2012; 18: 2108–2114.
-
- Salberg UB, Skingen VE, Fjeldbo CS, et al. A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients. Br J Cancer 2022; 127: 321–328.
-
- Turaka A, Buyyounouski MK, Hanlon AL, et al. Hypoxic prostate/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: long‐term results. Int J Radiat Oncol Biol Phys 2012; 82: e433–e439.
-
- Yang L, Roberts D, Takhar M, et al. Development and validation of a 28‐gene hypoxia‐related prognostic signature for localized prostate cancer. EBioMedicine 2018; 31: 182–189.
-
- Ragnum HB, Vlatkovic L, Lie AK, et al. The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer. Br J Cancer 2015; 112: 382–390.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials